<DOC>
	<DOCNO>NCT00061893</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinblastine , work different way stop tumor cell divide stop grow die . Celecoxib may stop growth Ewing 's sarcoma stopping blood flow tumor . Combining one chemotherapy drug celecoxib may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine low-dose vinblastine celecoxib standard regimens combination chemotherapy treat patient newly-diagnosed metastatic Ewing 's sarcoma family tumor .</brief_summary>
	<brief_title>Vinblastine , Celecoxib , Combination Chemotherapy Treating Patients With Newly-Diagnosed Metastatic Ewing 's Sarcoma Family Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility safety low-dose vinblastine celecoxib combination standard multiagent chemotherapy patient newly diagnose metastatic Ewing 's sarcoma family tumor . - Determine event-free survival patient treat regimen . - Determine pharmacokinetics regimen patient . OUTLINE : This pilot , multicenter study . - Induction therapy : Patients receive follow alternate regimen : - VAC ( course 1 3 ) : Patients receive vincristine IV cyclophosphamide IV 1 hour day 1 doxorubicin IV continuously day 1 2 week 1 7 . - IE ( course 2 4 ) : Patients receive ifosfamide IV 1 hour etoposide IV 1-2 hour day 1-5 week 4 10 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin 24-48 hour last dose chemotherapy continue blood count recover . Treatment repeat every 21 day total 4 course absence disease progression unacceptable toxicity . - Local control consolidation therapy : Beginning week 13 , patient assign 1 4 regimen base disease status . - Regimen A ( surgery ) : Patients respond induction chemotherapy undergo surgery week 13 . Patients begin consolidation therapy week 15 follow alternate regimen : - VAC ( course 5 , 7 , 9 ) : Patients receive VAC week 15 , 21 , 27 . - IE ( course 6 , 8 , 10 , 12 , 14 ) : Patients receive IE week 18 , 24 , 30 , 36 , 42 . - VC ( course 11 13 ) : Patients receive vincristine IV cyclophosphamide IV 1 hour week 33 39 . - Regimen B ( radiotherapy ) : Patients unresectable lesion undergo radiotherapy daily 5 day week approximately 6 week begin week 13 . Patients also receive consolidation therapy begin week 13 , follow alternate regimen : - VAC ( course 5 , 9 , 11 ) : Patients receive VAC week 13 , 25 , 31 . - IE ( course 6 , 8 , 10 , 12 , 14 ) : Patients receive IE week 16 , 22 , 28 , 34 , 40 . - VC ( course 7 13 ) : Patients receive VC week 19 37 . - Regimen C ( surgery radiotherapy ) : Patients respond induction chemotherapy undergo surgery week 13 . Patients inadequate margin surgery undergo radiotherapy ( regimen B ) begin week 15 . Patients also receive consolidation therapy , begin week 15 , follow alternate regimen : - VAC ( course 5 , 9 , 11 ) : Patients receive VAC week 15 , 27 , 33 . - IE ( course 6 , 8 , 10 , 12 , 14 ) : Patients receive IE week 18 , 24 , 30 , 36 , 42 . - VC ( course 7 13 ) : Patients receive VC week 21 39 . - Regimen D ( preoperative radiotherapy ) : Patients bulky lesion good clinical radiographic response induction therapy begin consolidation therapy week 13 VAC ( course 5 ) undergo concurrent radiotherapy regimen B . Patients receive IE week 16 19 course 6 7 . Patients undergo surgery week 22 . Patients continue consolidation therapy follow alternate regimen : - VAC ( course 8 9 ) : Patients receive VAC week 24 27 . - IE ( course 10 , 12 , 14 ) : Patients receive IE week 30 , 36 , 42 . - VC ( course 11 13 ) : Patients receive VC week 33 39 . Patients receive G-CSF SC ( induction therapy ) consolidation course . Consolidation therapy continue 10 course absence disease progression unacceptable toxicity . - Vinblastine celecoxib therapy : Throughout induction , local control , consolidation therapy , patient also receive vinblastine IV 3 time week ( twice week week vincristine give ) oral celecoxib twice daily , begin day 1 course 1 continue completion course 14 . * NOTE : *To ass safety , first 6 patient enrol receive vinblastine course 1 2 celecoxib add subsequent course . Patients follow every 3 month 3 year every 6 month 2 year . PROJECTED ACCRUAL : A total 6-36 patient accrue study within 1.17 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose Ewing 's sarcoma family tumor bone soft tissue Paraspinal tumor extradural origin Askin 's tumor chest wall eligible Metastatic disease , define follow criterion : Lesions discontinuous primary tumor , regional lymph node , share body cavity primary tumor A single pulmonary pleural nodule great 1 cm OR multiple nodule great 0.5 cm consider evidence pulmonary pleural metastasis ( unless another clear medical explanation lesion ) Contralateral pleural effusion consider metastatic disease No CNS involvement PATIENT CHARACTERISTICS : Age 50 ( diagnosis ) Performance status Lansky 50100 % ( 17 year age ) Karnofsky 50100 % ( age 17 ) Patients whose performance status affect pathological fracture allow provide able undergo treatment Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT less 5 time ULN Renal Creatinine adjust accord age follows* : No great 0.4 mg/dL ( â‰¤ 5 month ) No great 0.5 mg/dL ( 6 month 11 month ) No great 0.6 mg/dL ( 1 year23 month ) No great 0.8 mg/dL ( 2 years5 year ) No great 1.0 mg/dL ( 6 years9 year ) No great 1.2 mg/dL ( 10 years12 year ) No great 1.4 mg/dL ( 13 year [ female ] ) No great 1.5 mg/dL ( 13 year 15 year [ male ] ) No great 1.7 mg/dL ( 16 year [ male ] ) OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min* NOTE : *Unless value relate renal insufficiency secondary tumor involvement expect improve tumor mass small ( e.g. , pelvic mass cause obstructive hydronephrosis ) Cardiovascular Shortening fraction least 27 % echocardiogram OR Ejection fraction least 50 % MUGA Other Not pregnant nursing Fertile patient must use effective contraception Body surface area least 0.4 m^2 No allergy sulfa No aspirin hypersensitivity No asthma triad ( asthma nasal polyp , urticaria ) No prior cancer , include nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior bone marrow stem cell transplantation Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery Not specify Other No concurrent nonsteroidal antiinflammatory medication , include salicylates No concurrent dexrazoxane unless approve study investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>